Eli Lilly
Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials
February 5, 2019Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma
Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …
EMA rejects Lilly’s Lartruvo in soft tissue cancer following trial failure
January 24, 2019Sales and Marketing Cancer, EMA, Eli Lilly, Lartruvo, pharma
Eli Lilly has been dealt a blow as the European Medicines Agency announced its recommendation for soft tissue cancer patients …
Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma
January 21, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure
Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …
Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer
January 17, 2019Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma
Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …
Eli Lilly to buy Loxo Oncology in deal worth $8 billion
January 7, 2019Manufacturing and Production Cancer, Eli Lilly, Loxo Oncology, gene therapy, personalised medicine
US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in …
Top Ten most popular articles on Pharmafile.com this week!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …
Eli Lilly’s Taltz shows superiority over AbbVie’s Humira
December 18, 2018Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system
A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …
Eli Lilly’s Emgality cleared for treatment of migraine in Europe
November 20, 2018Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma
Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …
Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes
November 7, 2018Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes
Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …
Pfizer & Lilly’s non-opioid drug reduces pain in osteoarthritis
October 24, 2018Research and Development Eli Lilly, Pfizer, osteoarthritis, pharma
Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of …
GSK named third best UK workplace
October 22, 2018Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work
British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …
NICE rejects Elil Lilly’s Verzenio for breast cancer in draft guidance
October 19, 2018Medical Communications, Sales and Marketing Eli Lilly, NICE, UK, Verzenios, breast cancer, pharma
Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that …
Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer
October 3, 2018Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma
The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …
NICE recommends Eli Lilly’s psoriatic arthritis drug
August 9, 2018Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis
Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option …
Eli Lilly’s dulaglutide doses show blood control and weight benefits at Phase 2
June 25, 2018Research and Development, Sales and Marketing Eli Lilly, Trulicity, diabetes, pharma
Eli Lilly has announced new data on its once-weekly, injectable glucagon-like peptide Trulicity (dulaglutide 1.5mg) and investigational 3.0 and 4.5mg …
Latest content
